Corporate News 09-Feb-24
Biocon receives Complete Response Letter for Biologics License Application
From USFDA
Biocon announced that the U.S. Food and Drug Administration (US FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for bBevacizumab. The CRL did not identify any outstanding scientific issues on the dossier and informs the need for the completion of a pre-approval inspection of the bBevacizumab manufacturing facility.
Previous News
Indices trade with decent gains; realty shares rallied for 5th day
( Market Commentary - Mid-Session 17-May-24 12:40 )
Biocon to hold board meeting
( Corporate News - 11-Apr-24 16:18 )
Biocon Ltd up for third straight session
( Hot Pursuit - 23-May-24 13:05 )
Biocon AGM scheduled
( Corporate News - 17-May-24 13:47 )
Biocon Ltd drops for fifth straight session
( Hot Pursuit - 23-Feb-23 13:35 )
Biocon Biologics receives UDFDA approval for Yesafili™
( Corporate News - 21-May-24 09:13 )
Biocon's API unit in Bangalore receives GMP compliance certificate
( Corporate News - 08-Jun-23 16:30 )
Biocon
( Results - Analysis 16-Nov-22 18:05 )
Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA
( Hot Pursuit - 24-Jun-24 09:34 )
Biocon resumes uptrend after a day's pause; up over 9% in one month
( Hot Pursuit - 16-Nov-22 12:06 )
Biocon Ltd spurts 0.71%, rises for fifth straight session
( Hot Pursuit - 19-Jun-23 13:00 )
Other Stories
Time Technoplast repays commercial paper
03-Jul-24 18:31
Board of Aditya Vision approves stock split and listing of share on NSE
03-Jul-24 18:24
Pricol director resigns
03-Jul-24 18:21
Board of VMS Industries recommends first interim dividend
03-Jul-24 17:49
Lakshmi Machine Works to declare Quarterly Result
03-Jul-24 17:44
Modison to convene AGM
03-Jul-24 17:43
Sybly Industries to discuss results
03-Jul-24 17:43
Akme Fintrade (India) to announce Quarterly Result
03-Jul-24 17:43
Ponni Sugars (Erode) to hold board meeting
03-Jul-24 17:43
Aditya Vision to conduct AGM
03-Jul-24 17:43
Back
Top
